Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Dosage of PM012 in Mild Alzheimer's Disease
NCT05811000Phase 3Unknown
- Sponsor
- Mediforum
- Start
- Nov 2020
- Primary completion
- Feb 2021
- Modality
- Botanical Extract
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of PM012 in Alzheimer's disease (AD) (4 arms), sponsored by Mediforum. Primary endpoints: Alzheimer's Disease Assessment Scale-cognitive subscale at 12 weeks and Alzheimer's Disease Cooperative Study-Mild Cognitive Impairment- Activities of Daily Living Inventory at 12 weeks. Status: unknown.
02
Drugs
PM012
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05811000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05811000.